Stock listing

OTC:ANTH Anthera Pharmaceuticals Inc Stock

Follow Anthera Pharmaceuticals Inc into a list and get an email when it puts out news.

Anthera Pharmaceuticals Inc logo
Ticker
OTC:ANTH
Asset type
Stock
Exchange
OTC
Currency
USD

Anthera Pharmaceuticals Inc on 6ix

Decks
1 deck · latest Nov 13, 2012

Valuation

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.00

Events

QuarterResultsShare move
Quarter to Sep 30, 2024Nov 18, 20240.0%
Quarter to Jun 30, 2024Aug 7, 20240.0%
Quarter to Mar 31, 2024May 9, 20240.0%
Quarter to Dec 31, 2023Mar 5, 20240.0%
Quarter to Sep 30, 2023Nov 6, 20230.0%
Quarter to Jun 30, 2023Aug 9, 20230.0%
Quarter to Mar 31, 2023May 11, 20230.0%
Quarter to Dec 31, 2022Mar 7, 20230.0%
Quarter to Sep 30, 2022Nov 7, 20220.0%
Quarter to Jun 30, 2022Aug 10, 20220.0%
All 16 quarters
QuarterResultsShare move
Quarter to Mar 31, 2022May 12, 20220.0%
Quarter to Dec 31, 2021Mar 8, 20220.0%
Quarter to Sep 30, 2021Nov 8, 20210.0%
Quarter to Jun 30, 2021Aug 11, 2021−8.8%
Quarter to Mar 31, 2021May 13, 2021+7.5%
Quarter to Dec 31, 2020Mar 9, 2021−20.3%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2012)Technical7 slidesNov 13, 2012

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014FY2013FY2012
Revenue0145.0K3.19M000
Cost of revenue281.0K46.3K30.9K21.8M21.7K24.2K
Gross profit-281.0K98.7K3.15M-21.8M-21.7K-24.2K
Research and development28.6M46.3M30.9M21.8M21.7M49.2M
Selling, general and administrative7.94M11.1M7.57M6.62M6.56M6.71M
Operating income-36.4M-57.2M-35.2M-28.5M-28.2M-55.9M
Depreciation and amortization228.5K236.6K206.3K171.9K281.0K266.0K285.0K344.0K353.0K331.0K
EBITDA-36.2M-56.9M-35.0M-28.1M-27.9M-55.6M
Interest expense0001.05M2.60M3.35M
Income before tax-26.9M-55.5M-35.2M-29.6M-30.9M-59.4M
Income tax-9.94M-1.92M-308.0K705.0K2.25M3.02M
Net income-16.9M-53.6M-34.9M-30.3M-33.1M-59.4M
Earnings per share, basic-1.65-10.38-7.84-11.13-14.50-65.77

Balance sheet

LineFY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014FY2013FY2012
Cash and equivalents2.20M20.8M47.0M2.64M25.9M19.4M
Short-term investments000005.32M
Receivables326.0K
Inventory000000
Current assets3.19M22.7M47.9M3.02M26.3M24.8M
Property, plant and equipment482.0K763.0K263.0K468.0K812.0K1.15M
Goodwill000000
Total assets3.67M23.5M48.1M3.49M37.4M26.4M
Accounts payable1.83M4.78M5.26M2.23M3.52M5.21M
Current liabilities4.71M10.6M8.47M5.75M7.56M9.42M
Long-term debt000015.1M11.2M
Total debt17.9M20.6M
Total liabilities9.17M11.0M8.47M5.75M22.7M30.0M
Shareholders' equity-5.50M12.5M39.7M-2.26M14.8M-3.53M
Shares outstanding22.2M22.2M22.2M22.2M10.3M5.16M4.45M2.72M2.28M903.2K

Cash flow

LineFY2017FY2016FY2015FY2014FY2013FY2012
Cash from operations-36.9M-48.9M-30.9M-25.6M-31.9M-73.6M
Capital spending-919.9K-766.0K-80.0K-80.0K-15.0K-207.0K
Free cash flow-36.9M-49.7M-31.0M-25.6M-31.9M-73.8M
Cash from investing-919.9K-766.0K-80.0K10.0M-4.69M-3.78M
Cash from financing18.3M23.6M75.3M-7.71M43.1M31.3M
Dividends paid000000
Share buybacks270.0K6.72M75.3M10.4M-32-37
Change in cash-18.6M-26.1M44.3M-23.3M6.51M-46.2M

Open Financials

Cap table

Built by 6ix from Anthera Pharmaceuticals Inc’s releases

Common shares
26,179,302
Fully diluted
26,179,302

Fully diluted

LineShares
Common shares26,179,302

Share count over time

CountShares
Nov 22, 202626,179,302

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Craig Thompson
Other companies: Esperion Therapeutics, Inc. (Director · Since at least Jul 1, 2025); Tetraphase Pharmaceuticals Inc (Chief Operating Officer · Feb 3, 2014 – Sep 8, 2015 · Past); Trius Therapeutics Inc (Chief Commercial Officer · Mar 8, 2012 – Sep 11, 2013 · Past)
President & CEO, Director · Jan 7, 2016 – Jan 5, 2018 · Past
Brian R. Mueller
Other companies: BioMarin Pharmaceutical Inc. (Executive Vice President, Chief Financial Officer · Since at least Dec 31, 2011)
Director · Jun 18, 2014 – Jan 5, 2018 · Past
Charles V Olson
Other companies: Edesa Biotech, Inc. (Director · Since at least Dec 8, 2016)
Chief Technology Officer · Jan 5, 2016 – May 20, 2017 · Past
Philip SagerDirector · Jan 5, 2018 – Jan 5, 2018 · Past
Ursula FritschVP, Glob. Reg. & Compliance · Feb 23, 2010 – Jun 30, 2010 · Past

Open People

Log in to ask 6ix AI your own questions about Anthera Pharmaceuticals Inc.